Skip to content
Blackberry Empire – Lifestyle
Author:
AnaCardio
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
September 30, 2026
AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
June 25, 2026